title: Use of OKT3 monoclonal antibody as induction therapy for control of rejection in liver transplantation.
abstract: This report details a single center's experience with OKT3 induction immunosuppression for liver transplantation. One hundred ninety-nine consecutive, unselected adult liver recipients received OKT3 therapy for 9-10 days combined with low-dose steroids and azathioprine. Cyclosporine was begun to overlap with the last few days of OKT3 therapy. The average dose of OKT3 was 45 mg. Fifty-two patients (26.1%) experienced 57 episodes of acute rejection. The median time of onset of rejection was 18 days after grafting. Seventy-eight percent of the rejection episodes were steroid-sensitive. Recurrent rejection was uncommon and the need for OKT3 retreatment was infrequent. One year actuarial graft and patient survival was 79.7% and 82.3% respectively. Based on this evidence, it appears that OKT3 prophylaxis provides good control of acute rejection with a very low incidence of recurrent rejection.
authors: Department of Surgery, University Hospital, London, Ontario, Canada.
authors: W J
authors: WJ
authors: Wall
authors: C N
authors: CN
authors: Ghent
authors: A
authors: A
authors: Roy
authors: V C
authors: VC
authors: McAlister
authors: D R
authors: DR
authors: Grant
authors: P C
authors: PC
authors: Adams
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D016572:Cyclosporine / Q000008:administration & dosage; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D016031:Liver Transplantation / Q000401:mortality; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D012008:Recurrence; D015996:Survival Rate
chemical_list: D016853:Muromonab-CD3; D016572:Cyclosporine